1. Scrip
  2. >>Business

J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More

 
• By Jessica Merrill, Mandy Jackson, Emily Hayes, and Mary Jo Laffler

Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Regeneron CEO rebuffs Amgen’s patent battle strategy; Teva CEO apologizes for reduced financial guidance; Merck looks for more Keytruda wins, combos; Lilly awaits potentially differentiating Phase III CDK4/6 data; Alkermes readies ALKS 5461 depression submission; Biden discusses cancer moonshot; FDA’s real world evidence views; and UniQure turns a corner.

GoldKeyInPuzzle_1200x675

The legal battle between Amgen Inc. and Sanofi/Regeneron Pharmaceuticals Inc. is intensifying over rival PCSK9 blockers for high cholesterol – and words were exchanged in separate investor presentations at the J.P. Morgan Healthcare conference in San Francisco.

Amgen recently won an injunction blocking sales of Sanofi/Regeneron’s Praluent (alirocumab), which was found to infringe patents for Amgen’s Repatha (evolocumab). (Also see "‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales" - Scrip, 6 January, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip